<h4>Background</h4>Pazopanib hydrochloride (PZB) is a protein kinase inhibitor approved by the United States Food and Drug Administration and European agencies for the treatment of renal cell carcinoma and other renal malignancies. Here, WEE1 is linked to renal cell carcinoma.